Anil Diwan, PhD

Dr. Anil Diwan is President & Exec. Chairman of NanoViricides, Inc. He began working in nanomedicines circa 1992. He invented polymeric micelle-based zip-code-like site-directed targeting, multi-point attack, & guest drug encapsulating drug delivery platform. He has been key to design and development of the COVID drug candidates NV-CoV-2 and NV-CoV-2-R, the shingles drug candidate, NV-HHV-1, as well as several other drug candidates against many different viral diseases. He was instrumental in designing and establishing the NanoViricides campus in Shelton that comprises R&D to Clinical Trial Drug Substance and Drug Product Manufacturing facility. Dr. Diwan co-founded NanoViricides in 2005 as a public company (symbol: NNVC), and uplisted it in 2013 to NYSE-American. He has been instrumental in financing the Company through various equity raises to date. Dr. Diwan holds a PhD in (Bio)Chemical Engineering from Rice University and a BTech in Chemical Engineering from Indian Institute of Technology, Bombay (IITB).